AI is revolutionizing the drug life cycle by enhancing design, production, and patient dispensation. It aids in disease modeling, therapeutic target identification, and drug candidate optimization, addressing patient heterogeneity. AI-driven virtual screening and deep learning predict drug properties, significantly reducing preclinical tests and accelerating discovery. Quantum computing and generative adversarial networks promise further advancements. AI has already discovered novel drugs, shortening the discovery phase from 5 to 7 years to less than 2 years, suggesting a future surge in innovative pharmaceuticals. The integration of AI in Health Industry 4.0 is transforming drug discovery, production, and healthcare delivery. AI, alongside IoT, robotics, and cloud computing, enhances data exploitation, optimizes resources, and improves drug quality. Notable contributions to drug manufacturing include AI-driven predictive modeling, digital twins, and 3D printing in pharmaceuticals. Hospitals are adopting AI for improved patient care, personalized treatments, and more efficient operations. This digital transformation reduces costs and enhances productivity, as seen in Singapore’s advanced healthcare model. The future may yield a biomedical metaverse, revolutionizing healthcare ecosystems.